Alcon
- Market cap
- 30.45B
- P/E (TTM)i
- 48.09
- P/Bi
- 1.41
- EPSi
- 1.98
- Div yieldi
- 0.56%
- 52W posi
- 5%
Anonymous reader poll. Unscientific, not investment advice.
About Alcon
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner in 1945 and is headquartered in Geneva, Switzerland.
- Founded
- 1945
- CEO
- Mr. David J. Endicott
- Employees
- 25,942
- Headquarters
- Geneva, Geneve (Geneva), Switzerland
- Fiscal year end
- 12-31
- Website
- alcon.com
Company profile
- Exchange
- US
- Symbol
- ALC
- Market-cap rank
- #656
- Listing date
- 1970-01-01
- Market cap
- 30.45B
- Float cap
- 30.36B
- Shares out
- 483.40M
- Float shares
- 481.84M
Sectors & themes
Quote time 2026-10-08 07:24:50 · For reference only, not investment advice and not tailored to your situation.